Dr. Reddy's Laboratories (ADR)
Produces generics, branded medicines, biosimilars, active ingredients, and consumer health products.
Something off on this page? Send us feedback.
Profile
Sells prescription generics, branded generics, biosimilars, active pharmaceutical ingredients, and over-the-counter products across the United States, India, Russia and the CIS, China, Brazil, and Europe. Global Generics supplies most revenue, supported by PSAI and newer consumer-health portfolios.
Produces active pharmaceutical ingredients, prescription generics, branded generics, biosimilars, and over-the-counter products. Global Generics is the economic center, while Pharmaceutical Services and Active Ingredients supplies APIs and intermediates and newer portfolios extend into nutrition and nicotine replacement.
Operates from Hyderabad across major markets including the United States, India, Russia and the CIS, China, Brazil, and Europe. Its model combines in-house pharmaceutical manufacturing with country-level branded portfolios and acquired products, reflecting an access-to-medicines purpose rooted in its 1984 API origin.
U.S. sales depend on FDA product approvals and sustained manufacturing compliance. Portfolio expansion also depends on integrating acquired prescription, branded, nutrition, and consumer-health products across different regulatory and commercial systems.
Company facts
Key statistics
Year to date −12.1% · Average volume (30d) 2.7M
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 22, 2026Q1 FY27 | $0.09 | $0.06 | −34.7% | $850.6M | — | — | +3.69% |
| Jul 21, 2026Q1 FY27 | $0.09 | $0.06 | −34.7% | $850.6M | $835.7M | −1.7% | −9.39% |
| May 12, 2026Q4 FY26 | $0.09 | $0.06 | −33.3% | $886.6M | $789.1M | −11.0% | +4.25% |
| Jan 20, 2026Q3 FY26 | $0.16 | $0.16 | 0.0% | $927.7M | $951.6M | +2.6% | +2.63% |
Financial highlights
| 12 quarters | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|
| Revenue | $891.8M | $895.9M | $923.2M | $915.0M | $800.3M | $851.2M | |
| Gross profit | $495.5M | $509.8M | $504.7M | $490.7M | $358.7M | $395.9M | |
| Operating income | $185.0M | $183.2M | $183.6M | $149.3M | $5.0M | $31.2M | |
| Net income | $167.1M | $148.6M | $150.7M | $126.8M | $23.4M | $46.8M | |
| Diluted EPS | $0.20 | $0.18 | $0.18 | $0.15 | $0.03 | $0.06 | |
| Gross margin | 55.6% | 56.9% | 54.7% | 53.6% | 44.8% | 46.5% | |
| Operating margin | 20.7% | 20.5% | 19.9% | 16.3% | 0.6% | 3.7% |
Fiscal years (4-quarter sums)FY22 $1.09B · FY23 $1.27B · FY24 $2.21B · FY25 $3.41B · FY26 $3.53B
Revenue by geography · FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $853.7M · Total debt $754.4M · Total assets $6.03B · Shareholders' equity $4.02B
Dividends
Last raised to $0.0834 from $0.0643 in Jul 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jul 24, 2026 | Jul 9 | Aug 5 | $0.0834 | raised from $0.0643 |
| Jul 9, 2026 | Jul 9 | $0.0643 | cut from $0.0915 | |
| Jul 25, 2025 | Jul 10 | Aug 6 | $0.0915 | raised from $0.0808 split-adjusted |
| Jul 30, 2024 | Jul 15 | Aug 12 | $0.4762 | cut from $0.0976 split-adjusted |
| Jul 28, 2023 | Jul 10 | Aug 11 | $0.488 | |
| Jul 7, 2023 | Jul 10 | Aug 11 | $0.488 | raised from $0.0756 split-adjusted |
| Aug 1, 2022 | Jul 11 | Aug 12 | $0.325 | cut from $0.0774 split-adjusted |
| Jul 8, 2022 | Jul 11 | Jul 11 | $0.387 |
Ownership
Shares outstanding 832.95M · Float 832.95M · 100.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| K. Satish Reddy | 113.36M | 13.58% | 13D | Sep 18, 2025 |
| Robeco Institutional Asset Management B.V. | 18.02M | 2.16% | 13F | Jul 21, 2026 |
| Morgan Stanley | 10.94M | 1.31% | 13F | Aug 13, 2026 |
| BlackRock, Inc. | 10.59M | 1.27% | 13F | Aug 7, 2026 |
| Royal Bank of Canada | 9.21M | 1.11% | 13F | Aug 14, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Teva (ADR)
Broadest overlap in global, complex, and biosimilar medicines
- Viatris
Global rival across generics, established brands, and complex drugs
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Dr. Reddy's Laboratories (ADR) | $12.18 | 0.00% | $10.15B | 29.2 | 32.5 | 3.0 | −16.2% |
| Teva (ADR) | $36.30 | −0.36% | $42.44B | 60.7 | 12.9 | 2.5 | −0.8% |
| Viatris | $16.30 | −0.23% | $19.03B | — | 6.4 | 1.3 | +4.9% |
| Median | 60.7 | 9.6 | 1.9 | +2.0% |